Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia

Bibliographic Details
Main Authors: Cheung, Laurence, Cruickshank, Mark N, Hughes, Anastasia M, Singh, Sajla, Chua, Grace-Alyssa, Ford, Jette, Ferrari, Emanuela, Oommen, Joyce, Malinge, Sébastien, Lock, Richard B, Kees, Ursula R, Kotecha, Rishi S
Format: Journal Article
Language:English
Published: 2019
Subjects:
Infant
KMT2A
MLL
Pediatric Acute Lymphoblastic Leukemia
Romidepsin
Online Access:http://purl.org/au-research/grants/nhmrc/1059804
http://hdl.handle.net/20.500.11937/75658

Internet

http://purl.org/au-research/grants/nhmrc/1059804
http://hdl.handle.net/20.500.11937/75658

Similar Items